CPRX - Insider Transaction: Richard J Daly Sells $276K Worth Of Catalyst Pharmaceuticals Shares | Benzinga
Richard J Daly, President and CEO at Catalyst Pharmaceuticals (NASDAQ:CPRX), executed a substantial insider sell on June 5, according to an SEC filing.
What Happened: Daly's decision to sell 17,323 shares of Catalyst Pharmaceuticals was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday. The total value of the sale is $276,734.
Catalyst Pharmaceuticals shares are trading down 1.66% at $16.04 at the time of this writing on Thursday morning.
Get to Know Catalyst Pharmaceuticals Better
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
A Deep Dive into Catalyst Pharmaceuticals's Financials
Revenue Growth: Over the 3 months period, Catalyst Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 15.4% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Navigating Financial Profits:
-
Gross Margin: With ...